Ypsomed Holding AG - Annual Report 2022/ 23

Printed Matter

myclimate.org/01-23-392491

Ypsomed Holding AG

Annual Report 2022/23

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with more than 35 years' experience­. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies.

Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs over 2 000 employees.

Table of content

5

Table of content

  • Key figures
  • Letter to shareholders
    12 Engagement

14 Innovation & Digital Health

16  Ongoing development and digitisation

18  mylife Loop is a game changer for people with diabetes 20  We need to manage our growth in a responsible manner

22 Access & Expansion

24  Access to easy and high-qualityself-medication 26  New options for injecting drugs with large volumes 28  Treating obesity as a chronic disease

30 Responsibility & Engagement

32  On course in sustainability

40  Towards net zero emissions with sustainable plastics

42 Platforms & Operational Excellence

44  Increasing availability and expanding cost leadership

46  Energy generation and energy efficiency at the Schwerin site (DE) 48  Groundbreaking in China

50 Financial report 52  Profitable growth

54  Consolidated income statement 55  Consolidated balance sheet

56  Consolidated statement of cash flows

57  Consolidated statement of changes in equity 58  Basis for the consolidated fiinancial statements 64  Alternative Performance Measures

65  Notes to the consolidated financial statements 87  Statutory closing of Ypsomed Holding AG 97  Multi-year overview

98 Corporate Governance 102  Capital structure 104  Shareholder structure 105  Board of Directors 113  Executive Board

117  Remuneration, participations and loans 117  Shareholders' rights of participation

118  Change of control and blocking mechanisms 118  Auditors

119  Information policy

120 Remuneration Report

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Ypsomed Holding AG published this content on 24 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2023 14:06:02 UTC.